Growth and Restructuring: Biosynex in 2024

Biosynex SA recorded a 9% growth in its turnover in 2024, reaching 101.4 million euros. This increase is mainly due to a 20% increase in its export sales, as well as the robustness of its Pharmaceutical Division, which saw a 7% increase in its turnover.

The Diagnostics USA division recorded a notable growth of 46%, while the Diagnostics Europe division slightly declined by 3% due to the decline in sales of Covid-19-related products. As part of the restructuring, Biosynex closed unprofitable sites and sold assets, while carrying out workforce reductions. These measures are aimed at optimizing synergies and reducing debt through bank renegotiations. The restructuring is expected to result in savings of €7 million as early as 2025.